About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
MoreMenu
CloseWhite
About
Science
Publications
Team
News
Careers
Contact us
inWhite
tw_white-black
News
Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Cristiana Pires CEO receives Audience choice Award at BIOEurope Start-up Slam
Posted 26 November, 2019